Published in Microbiology on October 01, 2005
Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev (2010) 3.41
Helicobacter pylori dysregulation of gastric epithelial tight junctions by urease-mediated myosin II activation. Gastroenterology (2008) 1.41
The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal (2013) 1.11
Innate Immunity in the Female Reproductive Tract: Role of Sex Hormones in Regulating Uterine Epithelial Cell Protection Against Pathogens. Curr Womens Health Rev (2008) 0.98
Transcellular passage of Neisseria meningitidis across a polarized respiratory epithelium. Infect Immun (2010) 0.95
Targeting focal adhesions:Helicobacter pylori-host communication in cell migration. Cell Commun Signal (2008) 0.93
"Targeted disruption of the epithelial-barrier by Helicobacter pylori". Cell Commun Signal (2011) 0.92
Helicobacter pylori disrupts host cell membranes, initiating a repair response and cell proliferation. Int J Mol Sci (2012) 0.84
Inflammation and foveolar hyperplasia are reduced by supplemental dietary glutamine during Helicobacter pylori infection in mice. J Nutr (2009) 0.82
Tight junction disruption: Helicobacter pylori and dysregulation of the gastric mucosal barrier. World J Gastroenterol (2015) 0.79
Helicobacter pylori impedes acid-induced tightening of gastric epithelial junctions. Am J Physiol Gastrointest Liver Physiol (2013) 0.78
Toxoplasma gondii Infection Promotes Epithelial Barrier Dysfunction of Caco-2 Cells. J Histochem Cytochem (2016) 0.75
Bacterial serine protease HtrA as a promising new target for antimicrobial therapy? Cell Commun Signal (2017) 0.75
Helicobacter pylori gene silencing in vivo demonstrates urease is essential for chronic infection. PLoS Pathog (2017) 0.75
Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science (2003) 3.00
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet (2011) 2.82
Grb2 is a key mediator of helicobacter pylori CagA protein activities. Mol Cell (2002) 2.80
Helicobacter pylori cag-type IV secretion system facilitates corpus colonization to induce precancerous conditions in Mongolian gerbils. Gastroenterology (2005) 2.68
Helicobacter pylori dampens gut epithelial self-renewal by inhibiting apoptosis, a bacterial strategy to enhance colonization of the stomach. Cell Host Microbe (2007) 2.41
Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J Exp Med (2003) 2.28
VirB11 ATPases are dynamic hexameric assemblies: new insights into bacterial type IV secretion. EMBO J (2003) 2.23
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood (2004) 2.23
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood (2006) 2.15
A novel sheathed surface organelle of the Helicobacter pylori cag type IV secretion system. Mol Microbiol (2003) 2.11
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood (2008) 2.01
Integrin subunit CD18 Is the T-lymphocyte receptor for the Helicobacter pylori vacuolating cytotoxin. Cell Host Microbe (2008) 1.96
Deafness and renal tubular acidosis in mice lacking the K-Cl co-transporter Kcc4. Nature (2002) 1.84
Helicobacter pylori type IV secretion apparatus exploits beta1 integrin in a novel RGD-independent manner. PLoS Pathog (2009) 1.82
Strain-specific genes of Helicobacter pylori: genome evolution driven by a novel type IV secretion system and genomic island transfer. Nucleic Acids Res (2010) 1.80
Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica (2008) 1.74
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathog (2006) 1.68
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer (2006) 1.65
Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A (2007) 1.58
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma (2011) 1.58
Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood (2012) 1.57
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma (2007) 1.50
Delayed diagnosis and complications of Fanconi anaemia at advanced age--a paradigm. Br J Haematol (2006) 1.48
Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res (2003) 1.48
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica (2006) 1.48
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica (2009) 1.46
Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res (2009) 1.45
Essential role of ferritin Pfr in Helicobacter pylori iron metabolism and gastric colonization. Infect Immun (2002) 1.43
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biol Blood Marrow Transplant (2011) 1.43
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res (2011) 1.42
Protein subassemblies of the Helicobacter pylori Cag type IV secretion system revealed by localization and interaction studies. J Bacteriol (2008) 1.38
The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation. Eur J Pharmacol (2007) 1.35
CagA tyrosine phosphorylation and interleukin-8 induction by Helicobacter pylori are independent from alpAB, HopZ and bab group outer membrane proteins. Int J Med Microbiol (2002) 1.34
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer (2007) 1.34
BabA-mediated adherence is a potentiator of the Helicobacter pylori type IV secretion system activity. J Biol Chem (2011) 1.33
Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods (2002) 1.33
The novel Helicobacter pylori CznABC metal efflux pump is required for cadmium, zinc, and nickel resistance, urease modulation, and gastric colonization. Infect Immun (2006) 1.31
Functional and topological characterization of novel components of the comB DNA transformation competence system in Helicobacter pylori. J Bacteriol (2006) 1.31
Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol (2006) 1.27
No increase in age-specific incidence of myelodysplastic syndromes. Haematologica (2004) 1.27
Correlation between Helicobacter pylori OipA protein expression and oipA gene switch status. J Clin Microbiol (2004) 1.27
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol (2005) 1.26
Characterization of two cryptic Helicobacter pylori plasmids: a putative source for horizontal gene transfer and gene shuffling. J Bacteriol (2002) 1.23
Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int (2013) 1.21
Measurement of effector protein injection by type III and type IV secretion systems by using a 13-residue phosphorylatable glycogen synthase kinase tag. Infect Immun (2006) 1.21
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A (2007) 1.20
A C-terminal translocation signal is necessary, but not sufficient for type IV secretion of the Helicobacter pylori CagA protein. Mol Microbiol (2006) 1.20
Plasticity of repetitive DNA sequences within a bacterial (Type IV) secretion system component. J Exp Med (2003) 1.19
Sequencing, annotation, and comparative genome analysis of the gerbil-adapted Helicobacter pylori strain B8. BMC Genomics (2010) 1.18
Biochemical and functional characterization of Helicobacter pylori vesicles. Mol Microbiol (2010) 1.18
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One (2013) 1.17
Interaction of Helicobacter pylori with host cells: function of secreted and translocated molecules. Curr Opin Microbiol (2005) 1.17
Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med (2008) 1.15
Outer membrane protein expression profile in Helicobacter pylori clinical isolates. Infect Immun (2009) 1.15
Virulence mechanisms and persistence strategies of the human gastric pathogen Helicobacter pylori. Curr Top Microbiol Immunol (2009) 1.14
Helicobacter pylori cag-Pathogenicity island-dependent early immunological response triggers later precancerous gastric changes in Mongolian gerbils. PLoS One (2009) 1.14
Fut2-null mice display an altered glycosylation profile and impaired BabA-mediated Helicobacter pylori adhesion to gastric mucosa. Glycobiology (2009) 1.14
Primary human CD34+ hematopoietic stem and progenitor cells express functionally active receptors of neuromediators. Blood (2004) 1.12
The Helicobacter pylori CagF protein is a type IV secretion chaperone-like molecule that binds close to the C-terminal secretion signal of the CagA effector protein. Microbiology (2007) 1.11
Role of the alpAB proteins and lipopolysaccharide in adhesion of Helicobacter pylori to human gastric tissue. Int J Med Microbiol (2002) 1.09
Two-component systems of Helicobacter pylori contribute to virulence in a mouse infection model. Infect Immun (2003) 1.08
Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. Br J Haematol (2011) 1.08
Helicobacter pylori BabA expression, gastric mucosal injury, and clinical outcome. Clin Gastroenterol Hepatol (2006) 1.08
Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica (2005) 1.07
Functional and intracellular signaling differences associated with the Helicobacter pylori AlpAB adhesin from Western and East Asian strains. J Biol Chem (2007) 1.06
Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica (2011) 1.06
Nitric oxide specifically reduces the permeability of Cx37-containing gap junctions to small molecules. J Cell Physiol (2005) 1.05
Treatment of severe hemorrhagic cystitis after allogeneic stem cell transplantation with palifermin, a recombinant human keratinocyte growth factor. Biol Blood Marrow Transplant (2007) 1.05
Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med (2007) 1.04
Colonization of C57BL/6J and BALB/c wild-type and knockout mice with Helicobacter pylori: effect of vaccination and implications for innate and acquired immunity. Infect Immun (2003) 1.04
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res (2012) 1.03
Type IV secretion systems in pathogenic bacteria. Int J Med Microbiol (2002) 1.01
Topological analysis of a putative virB8 homologue essential for the cag type IV secretion system in Helicobacter pylori. Int J Med Microbiol (2003) 1.01
The RecA protein of Helicobacter pylori requires a posttranslational modification for full activity. J Bacteriol (2004) 1.01
Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun (2003) 1.01
Topology and membrane interaction of Helicobacter pylori ComB proteins involved in natural transformation competence. Int J Med Microbiol (2003) 1.00
Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol (2008) 0.99
Structure of Helicobacter pylori catalase, with and without formic acid bound, at 1.6 A resolution. Biochemistry (2004) 0.99
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol (2008) 0.98
CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler (2010) 0.98
Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol (2006) 0.98
Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res (2012) 0.98
Activation of Helicobacter pylori CagA by tyrosine phosphorylation is essential for dephosphorylation of host cell proteins in gastric epithelial cells. Mol Microbiol (2002) 0.97
Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica (2007) 0.97
Structural insights into Helicobacter pylori oncoprotein CagA interaction with β1 integrin. Proc Natl Acad Sci U S A (2012) 0.97